← Back to Search

Remimazolam vs Midazolam for Cataract

Phase 4
Waitlist Available
Led By Zhuang Fang, MD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up postop day 0 (day of surgery) until discharge from the hospital, usually on postop day 1 (an average of 1 day).
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing two anxiety-reducing medications, Midazolam and Remimazolam, in elderly patients having cataract surgery. The goal is to see if Remimazolam causes fewer cognitive side effects compared to Midazolam. Patients will take a cognitive test to measure any changes. Remimazolam is a newly developed medication with quicker effects than Midazolam.

Who is the study for?
This trial is for adults over 65 who are having their first cataract surgery at UCLA and can follow simple English commands. They should be in stable health but not severely overweight, have sleep apnea, chronic pain on opiates, or a history of certain allergies or substance abuse.
What is being tested?
The study compares the effects of two sedatives—Midazolam and Remimazolam—on patients' cognitive function after cataract surgery. Cognitive changes are measured using the MoCA test before surgery, upon discharge from post-op care, and the following day.
What are the potential side effects?
Potential side effects may include drowsiness, confusion, impaired coordination, memory problems immediately after waking up from anesthesia. These drugs could also cause allergic reactions or interact with other medications.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day of surgery
This trial's timeline: 3 weeks for screening, Varies for treatment, and day of surgery for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in MoCA Scores in PACU and the next day between midazolam and remimazolam group.
Change in MoCA score following surgery in the PACU and post operative day 1.
Length of postoperative stay
Secondary study objectives
Patient Satisfaction
Surgeon Satisfaction

Side effects data

From 2016 Phase 3 trial • 461 Patients • NCT02290873
39%
Hypotension
20%
Hypertension
11%
Bradycardia
10%
Diastolic Hypertension
8%
Tachycardia
8%
Diastolic Hypotension
5%
Systolic hypertension
2%
Nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Remimazolam
Placebo
Midazolam

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: InterventionExperimental Treatment1 Intervention
Patients assigned to the study group will receive Remimazolam.
Group II: ControlActive Control1 Intervention
Patients assigned to the control group will receive Midazolam.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Remimazolam
2022
Completed Phase 4
~2870

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for cognitive impairment, such as Midazolam and Remimazolam, work by enhancing the activity of the GABA-A receptor, which increases inhibitory effects in the brain. This mechanism can help manage symptoms like anxiety and agitation in cognitive impairment patients. Remimazolam, with its shorter duration of action, may provide advantages in terms of fewer side effects and faster recovery compared to longer-acting benzodiazepines.
Factors contributing to the decay of the stimulus-evoked IPSC in rat hippocampal CA1 neurons.Behavioral and biochemical characterization of benzodiazepine receptor partial agonists in pigeons.Allopregnanolone and perampanel as adjuncts to midazolam for treating diisopropylfluorophosphate-induced status epilepticus in rats.

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,566 Previous Clinical Trials
10,263,334 Total Patients Enrolled
Zhuang Fang, MDPrincipal InvestigatorUniversity of California, Los Angeles

Media Library

Intervention Clinical Trial Eligibility Overview. Trial Name: NCT05980117 — Phase 4
Cognitive Impairment Research Study Groups: Intervention, Control
Cognitive Impairment Clinical Trial 2023: Intervention Highlights & Side Effects. Trial Name: NCT05980117 — Phase 4
Intervention 2023 Treatment Timeline for Medical Study. Trial Name: NCT05980117 — Phase 4
~48 spots leftby May 2025